ASCO continues to partner with state societies on cancer policy priorities under consideration in states across the country.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
On April 2, ASCO released a video that features several physicians who work at various practice types that have achieved Quality Oncology Practice Initiative (QOPI®) Certification discussing what this certification means to them, their staff, and their patients.
Eligible clinicians participating in the Quality Payment Program (QPP) will now be able to submit 2017 Merit-based Incentive Payment System (MIPS) performance data until Tuesday, April 3, 2018 at 8:00 PM ET. Clinicians can submit their 2017 performance data using the QPP website.
Linda D. Bosserman, MD, FACP, FASCO, has been named Editor-in-Chief of the Journal of Oncology Practice (JOP), a publication of ASCO. Dr. Bosserman is a recognized leader in cancer care delivery with a deep understanding of the issues impacting all types of oncology practices.
On March 29, 2018, the Food and Drug Administration granted accelerated approval to blinatumomab (Blincyto®, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
The American Society of Clinical Oncology (ASCO) applauds Congress for its bipartisan support of the omnibus spending bill that significantly boosts our nation's investment in biomedical research. By providing a $3 billion funding increase for the National Institutes of Health (NIH) for fiscal year (FY) 2018—the biggest NIH funding increase in 15 years—Congress has taken bold action to regain much-needed momentum in cancer research following a decade of stagnant funding for the NIH
On March 22, 2018, the Food and Drug Administration approved nilotinib (TASIGNA®, Novartis Pharmaceuticals Corporation) for pediatric patients 1 year of age or older with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.
The second year of the Quality Payment Program (QPP), established by the Medicare Access and CHIP Reauthorization Act (MACRA), began on Jan. 1, 2018. This year, oncology practices face more robust quality reporting requirements to successfully participate in QPP and avoid a financial penalty in 2020.
On March 20, 2018, the Food and Drug Administration approved brentuximab vedotin (Adcetris®, Seattle Genetics, Inc.) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
In a letter to the Committee on Education and the Workforce Subcommittee on Health, Employment, Labor and Pensions leadership, ASCO and 25 other healthcare groups asked the House Subcommittee to consider the Restoring the Patients Voice Act of 2017 (H.R. 2077), which provides patient protections against step therapy protocols imposed by private sector health plans..
The ASCO Insurance Coverage of Clinical Trials Toolkit is available to assist research sites with issues related to insurance coverage for patients participating in clinical trials. Developed by the ASCO Research Community Forum (RCF), the free toolkit contains sample checklists, templates, and forms to help sites determine insurance coverage for clinical trials, deal with coverage denials, and navigate the appeals process.
In a new ASCO in Action Podcast, ASCO Vice President of Clinical Affairs Stephen Grubbs, MD, FASCO, joins ASCO CEO Dr. Clifford A. Hudis, FACP, FASCO, to break down the Quality Payment Program (QPP) and discuss the reimbursement changes coming to oncology practices in the United States.
On June 22, ASCO and the Food and Drug Administration will co-host an event, the Core Outcome Assessments in Cancer Clinical Trials workshop.
On March 22-23, the National Cancer Institute (NCI) will host a free meeting on Cancer, Autoimmunity, and Immunology.
ASCO's new social media tolkit helps members raise awareness of the National Cancer Institute's important role in advancing cancer research.